Monaco Asset Management’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-309,211
Closed -$959K 84
2025
Q4
$959K Sell
309,211
-1,070,205
-78% -$3.05M 0.17% 65
2025
Q3
$3.63M Sell
1,379,416
-2,170,584
-61% -$4.78M 0.22% 43
2025
Q2
$4.37M Sell
3,550,000
-1,299,134
-27% -$1.42M 0.77% 25
2025
Q1
$5.33M Sell
4,849,134
-522,507
-10% -$604K 1.09% 17
2024
Q4
$4.86M Buy
5,371,641
+1,520,721
+39% +$1.3M 0.7% 21
2024
Q3
$3.8M Buy
3,850,920
+1,124,816
+41% +$1.08M 0.55% 30
2024
Q2
$2.46M Buy
2,726,104
+2,170,104
+390% +$1.62M 0.39% 29
2024
Q1
$656K Buy
556,000
+276,000
+99% +$304K 0.2% 47
2023
Q4
$256K Buy
+280,000
New +$207K 0.08% 72

Other funds holding GOSS

Monaco Asset Management's GOSS Position: Q1 2026 in Review

Monaco Asset Management sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 309,211 shares — an estimated $959K sold.

Monaco Asset Management first reported a position in GOSS in Q4 2023 and held it in 9 quarters. The position peaked at $5.33M in Q1 2025. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Monaco Asset Management reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Monaco Asset Management sold 309,211 Gossamer Bio shares in Q1 2026, an estimated $959K.
  • Monaco Asset Management first reported a position in Gossamer Bio in Q4 2023 and held it in 9 quarters.
  • Monaco Asset Management's Gossamer Bio position peaked at $5.33M in Q1 2025.
  • 184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Monaco Asset Management's 13F filing for Q1 2026, filed 11 May 2026.